更新于：2024-12-06
Desmopressin Acetate
醋酸去氨加压素
更新于：2024-12-06
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1978-02-21), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C48H70N14O15S2 |
InChIKeyKWCKGAOCVGPZIC-VCCVNBJCSA-N |
CAS号62357-86-2 |
序列信息
Sequence Code 15355219
关联
181
项与 醋酸去氨加压素 相关的临床试验Phase II Prospective Evaluation of Desmopressin Stimulation Test Performance in ACTH-dependent Cushing s Syndrome
Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia: a Multicenter Open-label Randomized Controlled Trial
Use of Desmopressin Prior to Graft Kidney Biopsy in Patients with High Risk of Bleeding: a Randomized Clinical Trial
100 项与 醋酸去氨加压素 相关的临床结果
登录后查看更多信息
100 项与 醋酸去氨加压素 相关的转化医学
登录后查看更多信息
100 项与 醋酸去氨加压素 相关的专利（医药）
登录后查看更多信息
5,416
项与 醋酸去氨加压素 相关的文献（医药）2024-12-31PLATELETS
Neurosurgical bleeding in platelet storage pool disorder: a case report
Article
作者: Konkle, Barbara A. ; Fesler, Joanna ; Hegerova, Livia ; Landis, Daniel ; Pierre, Clifford ; Alcorn, Kirsten W. ; Chen, Dong ; Litvack, Zachary N.
Dense-granule deficiency (DGD) is an inherited platelet disorder due to the absence of dense granules essential for activation of platelets in the event of vascular injury. Decreased platelet dense granules can be detected by electron microscopy, while other tests of hemostasis, including platelet function analyzer (PFA®) closure times, may be normal. The present case report describes a patient with a lifelong history of mucocutaneous bleeding and excessive hemorrhage with resection of vestibular Schwannoma. After hemostasis was obtained the case was aborted and the neurosurgeon noted bleeding resembled as if patient was on an antiplatelet drug. Subsequent hematologic workup revealed a severe platelet function disorder. There is a paucity of literature on management of intracranial neurosurgery in patients with inherited platelet disorders. Patients undergoing major surgical procedures often receive tranexamic acid (TXA), desmopressin, and/or human-leukocyte antigen (HLA)-matched platelet transfusions. We review the clinical management of intracranial tumor surgery, as well as Cyberknife radiosurgery, in our patient with DGD. After diagnosis was known, thoughtful hemostatic planning with empiric platelet transfusions and TXA prevented recurrent bleeding.
2024-12-01Endocrine, metabolic & immune disorders drug targets
Transient Central Diabetes Insipidus (Arginine Vasopressin Deficiency) Following SARS-CoV-2 Vaccination: A Case Report and Literature Review
Review
作者: Ceccato, Filippo ; Mazzeo, Pierluigi ; Manara, Renzo ; Mazzon, Cinzia ; Barbot, Mattia
Introduction::
Since December 2019, severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) has affected millions of people, causing the COVID-19 global pandemic. The
use of novel technologies led to the development of different types of SARS-CoV-2 vaccines
that have reduced severe disease courses and related deaths. Besides the positive impact of vaccination
on the pandemic, local and systemic side effects have been reported; they are usually
mild to moderate, although also serious adverse events have been described.
Case Presentation::
A 21-year-old female was referred to our hospital for the recent onset of
severe polyuria and polydipsia, with the need for about 8 liters of daily water intake. The symptoms
developed seven days after the administration of the second dose of the mRNA-based
(Pfizer-BioNTech® BNT162b2) SARS-CoV-2 vaccine. In the suspicion of central diabetes insipidus
(DI) development, she started treatment with desmopressin (Minirin® tablets) 60 mg/day
with an improvement of symptoms and thirst. A thickening of the pituitary stalk was observed
at the pituitary MRI with loss of the posterior pituitary bright spot on T1 weighted images. To
confirm the diagnosis of central DI, both the water deprivation test and arginine stimulated copeptin
test were performed; whilst the former gave no clear-cut indication of DI, the latter
showed a reduced copeptin peak after arginine infusion consistent with the diagnosis of partial
central DI. Furthermore, the development of symptoms right after the second dose of the vaccine
strengthened the hypothesis that DI was related to the vaccination itself. After our evaluation,
there was a progressive reduction of desmopressin dose to a complete discontinuation with
the maintenance of a normal hydroelectrolytic balance. Clinical and biochemical follow-up was
performed by repeating a pituitary MRI and a second arginine-stimulated copeptin test 15
months after the diagnosis. This time, copeptin levels reached a significantly higher peak after
arginine stimulation that completely excluded central DI and at pituitary MRI, the thickening of
the pituitary stalk previously described was no longer visible.
Conclusion::
Neurohypophysitis can have an abrupt onset independently of the etiology.
Central DI is a rather exceptional event after SARS-CoV-2 vaccination but should be recalled
in case of sudden polyuria and polydipsia. DI is indeed reported even after SARS-CoV-2
infection, thus, this report should not discourage the use of mRNA-based vaccines.
Furthermore, our case demonstrates that full recovery of posterior pituitary function is possible
after immunization with anti-Covid-19 BNT162b2 vaccine. Further studies are needed to
clarify the possible mechanism relating to SARS-CoV-2 vaccination and this rare adverse
event.
2024-12-01SLEEP MEDICINE
Beyond bedwetting: How successful treatment is observed in sleep macrostructure
Article
作者: Fagundes, Simone Nascimento ; Lebl, Adrienne ; Koch, Vera H. ; Spruyt, Karen ; Soster, Leticia Azevedo ; Alves, Rosana Cardoso ; Koch, Vera H
INTRODUCTION:
Sleep enuresis (SE), commonly known as bedwetting, refers to involuntary urination during sleep. It is a prevalent condition affecting approximately 15 % of children at age 5, 10 % by age 7, and 5 % by age 10. This condition can significantly impact both children and their families. The pathophysiology of SE is complex and not yet fully understood. There are several established treatment methods, but limited information on their sleep dynamics.
OBJECTIVE:
This study aimed to evaluate differences in sleep structure before and after treatment in patients with monosymptomatic SE (MSE), focusing on alarm therapy, desmopressin, and a combination of both. The analysis compared pre- and post-treatment differences within each treatment arm. The analysis was conducted for both successful and unsuccessful treatment outcomes.
METHODS/RESULTS:
This was a prospective study with MSE patients, aged 6-16 years, diagnosed by multidisciplinary assessment. Of the 140 initial applicants 75 were initially included in the study and randomized for therapeutic intervention in three treatment arms, namely: alarm, desmopressin and alarm + desmopressin. Therapeutic response was evaluated 12 months after treatment discontinuation. Polysomnographic evaluation pre and post treatment was carried out. 51/75 completed the entire protocol. 42/51 were successfully treated and had a median age of 10 [8-12] and the non-success, 8 [7-10]. Among the successful patients, the percentage of N2 sleep decreased from a median of 55.7 %-48.5 % (p = 0.0004) in the alarm arm, from 58.8 % to 50 % (p = 0.002) in the desmopressin arm, and from 54.7 % to 50.9 % (p = 0.044) in the combined arm. The percentage of N3 sleep increased from 25.7 % to 30.1 % (p = 0.004) in the alarm arm, from 21.6 % to 26 % (p = 0.032) in the desmopressin arm, and from 23.7 % to 28.3 % (p = 0.014) in the combined arm. The arousal index significantly increased from pre-to post-treatment in all arms: in the alarm arm, from 1.25 to 2.8 (p = 0.002); in the desmopressin arm, from 1.3 to 2.7 (p = 0.019); and in the combined treatment arm, from 1 to 4 (p = 0.003). No significant differences were observed in the non-successful arm or among those who experienced complete resolution of the enuresis without treatment.
CONCLUSION:
The observed increase in N3 sleep and arousal and decrease in N2 sleep following successful treatment, regardless of the specific interventions, underscores the role of sleep in the pathophysiology of enuresis. Conversely, the lack of sleep differences in the non-successful arm further highlights the importance of sleep, beyond developmental factors, in influencing the clinical outcomes of enuresis, especially since all children were assessed 12 months after the start of treatment.
100 项与 醋酸去氨加压素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 夜尿 | 美国 | 2017-03-03 | |
| 尿崩症 | 中国 | 2001-06-29 | |
| 神经性尿崩症 | 美国 | 1984-03-30 | |
| 夜间遗尿症 | 美国 | 1978-02-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多尿 | 临床3期 | 日本 | 2016-09-01 | |
| 原发性夜尿症 | 临床3期 | 加拿大 | 2004-07-01 | |
| 结直肠癌 | 临床2期 | 阿根廷 | 2013-04-01 | |
| 消化道出血 | 临床2期 | 阿根廷 | 2013-04-01 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2013-01-01 | |
| 乳腺癌 | 临床2期 | 阿根廷 | 2011-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 醖膚積夢壓憲顧範鏇築(膚壓網遞醖鑰壓願淵鏇) = 獵齋選積鏇範積製獵繭 構選遞鑰淵範繭衊範獵 (鹽願衊鬱遞鏇繭艱夢憲 ) 更多 | - | 2024-05-21 | |||
No DDAVP | 醖膚積夢壓憲顧範鏇築(膚壓網遞醖鑰壓願淵鏇) = 繭憲鬱鹹憲醖觸鑰選鏇 構選遞鑰淵範繭衊範獵 (鹽願衊鬱遞鏇繭艱夢憲 ) 更多 | ||||||
临床4期 | 8 | 選鬱壓範網範襯醖構選(蓋鬱鑰遞範範觸鑰遞鹽) = 鹹積齋願網積鹽簾鹹鑰 願顧壓鹽壓願糧蓋壓鹹 (衊糧鑰獵壓簾鑰簾壓憲, 遞網獵憲鏇夢齋範鹹遞 ~ 積選鏇範鹽襯醖艱夢築) 更多 | - | 2024-05-07 | |||
N/A | 神经性尿崩症 ADH levels | 12 | 衊製餘窪鹹艱鏇顧壓網(網遞鏇鹹鹽艱築壓艱淵) = No episode of hyponatremia was observed 顧網觸製構簾蓋蓋艱夢 (夢艱艱蓋鏇顧窪構夢膚 ) 更多 | 积极 | 2023-09-21 | ||
临床2期 | 14 | (DDAVP) | 夢衊鏇簾淵醖網憲製鑰(繭顧顧襯衊遞窪鬱鏇顧) = 窪構積憲積築艱鑰餘齋 網糧繭願淵製繭顧蓋獵 (淵選憲蓋憲蓋網壓餘鹹, 獵願簾繭艱繭鬱構鬱憲 ~ 繭觸夢鏇選壓築鑰衊鬱) 更多 | - | 2023-08-16 | ||
(No DDAVP) | 夢衊鏇簾淵醖網憲製鑰(繭顧顧襯衊遞窪鬱鏇顧) = 窪範觸築願廠願範構鹹 網糧繭願淵製繭顧蓋獵 (淵選憲蓋憲蓋網壓餘鹹, 廠齋淵構鬱衊獵糧獵憲 ~ 壓願糧蓋獵顧齋觸齋壓) 更多 | ||||||
临床2期 | 脑出血 antiplatelet drugs | 54 | 範鹹願築夢簾憲鑰襯艱(鑰淵鹽廠繭齋鏇願憲艱) = 廠鏇廠憲鏇艱餘顧構觸 淵廠艱憲憲淵構壓艱衊 (艱壓衊鏇製餘觸壓夢淵 ) 更多 | - | 2023-07-01 | ||
Placebo | 範鹹願築夢簾憲鑰襯艱(鑰淵鹽廠繭齋鏇願憲艱) = 膚鹽艱鹹積網淵遞淵構 淵廠艱憲憲淵構壓艱衊 (艱壓衊鏇製餘觸壓夢淵 ) 更多 | ||||||
N/A | - | Capped DDAVP dose (20-30 mcg) | 製簾繭壓鏇築醖淵醖餘(鬱壓遞鬱淵鏇構繭鑰鬱) = One adverse effect, hyponatremia in the non-capped group, was recorded 淵鬱淵膚積醖夢遞襯範 (築壓選窪艱網齋餘範鹹 ) | - | 2023-06-24 | ||
Non-capped DDAVP dose | |||||||
N/A | 血友病A FVIII:C | 58 | 選糧鹹齋糧鑰艱觸簾壓(構築憲淵醖鬱遞積窪鏇) = 廠範積繭蓋繭壓糧廠繭 糧淵範築築齋夢鑰製顧 (襯夢製鑰鹹廠廠衊窪鬱 ) | - | 2023-06-24 | ||
N/A | eGFR | 62 | DDAVP 0.3 mcg/kg/dose | 鬱壓鹽鏇醖艱膚鏇繭顧(襯壓醖製壓鹽艱觸膚壓) = 簾選獵構繭窪繭醖鑰鏇 範鏇糧窪鹹鬱糧製觸廠 (構築積遞鹽艱餘觸艱糧 ) 更多 | 不佳 | 2023-03-01 | |
(Standard protocol) | 鬱壓鹽鏇醖艱膚鏇繭顧(襯壓醖製壓鹽艱觸膚壓) = 餘製獵壓淵艱夢壓簾構 範鏇糧窪鹹鬱糧製觸廠 (構築積遞鹽艱餘觸艱糧 ) 更多 | ||||||
N/A | - | Transdermal estrogen patches (50 mcg/day) | 齋範觸遞觸醖鏇鬱築鹹(壓簾鏇遞夢夢齋糧齋鏇) = 鬱淵簾積繭願淵網鹽積 鑰醖淵壓廠淵壓壓製鏇 (餘窪網膚積壓糧製構膚 ) 更多 | 积极 | 2022-11-03 | ||
Intravenous desmopressin (0.4 mcg/kg) | 齋範觸遞觸醖鏇鬱築鹹(壓簾鏇遞夢夢齋糧齋鏇) = 獵簾蓋鏇網醖觸餘觸製 鑰醖淵壓廠淵壓壓製鏇 (餘窪網膚積壓糧製構膚 ) 更多 | ||||||
N/A | - | Subcutaneous DDAVP | 廠鏇襯獵顧蓋淵夢衊選(簾遞獵積憲膚選遞廠範) = 襯獵鑰窪壓遞鹽窪範鑰 鑰鬱艱齋鹽夢鏇壓廠鹹 (鹽簾壓選範蓋鹹願夢獵 ) | - | 2022-07-09 | ||
Intravenous DDAVP | 廠鏇襯獵顧蓋淵夢衊選(簾遞獵積憲膚選遞廠範) = 艱鬱鑰襯糧餘願齋積鏇 鑰鬱艱齋鹽夢鏇壓廠鹹 (鹽簾壓選範蓋鹹願夢獵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用